Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angiogenesis Inhibitors | 2 | 2015 | 77 | 0.780 |
Why?
|
| Anesthetics, Local | 2 | 2012 | 71 | 0.720 |
Why?
|
| Intravitreal Injections | 3 | 2015 | 49 | 0.590 |
Why?
|
| Endophthalmitis | 2 | 2015 | 12 | 0.550 |
Why?
|
| Propoxycaine | 2 | 2012 | 5 | 0.480 |
Why?
|
| Lidocaine | 2 | 2012 | 33 | 0.480 |
Why?
|
| Anterior Eye Segment | 1 | 2015 | 6 | 0.470 |
Why?
|
| Diabetic Retinopathy | 1 | 2015 | 53 | 0.440 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 206 | 0.420 |
Why?
|
| Triamcinolone Acetonide | 2 | 2009 | 14 | 0.360 |
Why?
|
| Eye Pain | 1 | 2011 | 4 | 0.360 |
Why?
|
| Anesthesia, Local | 1 | 2011 | 20 | 0.360 |
Why?
|
| Macular Degeneration | 2 | 2011 | 187 | 0.350 |
Why?
|
| Glucocorticoids | 2 | 2009 | 188 | 0.320 |
Why?
|
| Photochemotherapy | 1 | 2008 | 24 | 0.280 |
Why?
|
| Choroid | 1 | 2008 | 26 | 0.280 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 49 | 0.280 |
Why?
|
| Choroidal Neovascularization | 1 | 2008 | 28 | 0.280 |
Why?
|
| Ranibizumab | 2 | 2015 | 20 | 0.210 |
Why?
|
| Bevacizumab | 2 | 2015 | 59 | 0.200 |
Why?
|
| Vitreous Body | 3 | 2011 | 31 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 234 | 0.180 |
Why?
|
| Ophthalmology | 1 | 2018 | 24 | 0.140 |
Why?
|
| Visual Acuity | 2 | 2009 | 125 | 0.140 |
Why?
|
| Macular Edema | 2 | 2015 | 24 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2015 | 3263 | 0.120 |
Why?
|
| Photometry | 1 | 2015 | 7 | 0.120 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 33 | 0.120 |
Why?
|
| Retinal Vein Occlusion | 1 | 2015 | 18 | 0.120 |
Why?
|
| Wet Macular Degeneration | 1 | 2015 | 26 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 432 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 417 | 0.110 |
Why?
|
| Male | 7 | 2018 | 29587 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 495 | 0.100 |
Why?
|
| Female | 6 | 2018 | 32579 | 0.090 |
Why?
|
| Tetracaine | 1 | 2011 | 7 | 0.090 |
Why?
|
| Injections | 2 | 2009 | 81 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2011 | 5408 | 0.090 |
Why?
|
| Fluorescein Angiography | 2 | 2008 | 58 | 0.090 |
Why?
|
| Visual Field Tests | 1 | 2009 | 24 | 0.080 |
Why?
|
| Hydroxychloroquine | 1 | 2009 | 21 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2011 | 341 | 0.080 |
Why?
|
| Fovea Centralis | 1 | 2009 | 17 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 869 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2011 | 736 | 0.080 |
Why?
|
| Retinal Diseases | 1 | 2009 | 33 | 0.080 |
Why?
|
| Uveomeningoencephalitic Syndrome | 1 | 2008 | 3 | 0.070 |
Why?
|
| Vascular Neoplasms | 1 | 2008 | 17 | 0.070 |
Why?
|
| Porphyrins | 1 | 2008 | 7 | 0.070 |
Why?
|
| Photosensitizing Agents | 1 | 2008 | 17 | 0.070 |
Why?
|
| Humans | 8 | 2018 | 62915 | 0.070 |
Why?
|
| Lymphoma | 1 | 2008 | 101 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 112 | 0.070 |
Why?
|
| Antirheumatic Agents | 1 | 2009 | 219 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 463 | 0.060 |
Why?
|
| Aged | 3 | 2018 | 14271 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2009 | 6555 | 0.040 |
Why?
|
| Consumer Behavior | 1 | 2018 | 36 | 0.040 |
Why?
|
| Risk Factors | 1 | 2008 | 5311 | 0.030 |
Why?
|
| Trust | 1 | 2018 | 73 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2018 | 284 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 518 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 707 | 0.020 |
Why?
|
| Middle Aged | 3 | 2018 | 17403 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2553 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2654 | 0.020 |
Why?
|
| Arthritis | 1 | 2009 | 53 | 0.020 |
Why?
|
| Retina | 1 | 2009 | 124 | 0.020 |
Why?
|
| Prednisolone | 1 | 2008 | 8 | 0.020 |
Why?
|
| Vincristine | 1 | 2008 | 27 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2008 | 33 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 79 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 58 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2008 | 62 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 87 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2008 | 99 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2008 | 64 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2009 | 5606 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 431 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2009 | 223 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 990 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 968 | 0.010 |
Why?
|
| Skin | 1 | 2008 | 377 | 0.010 |
Why?
|
| United States | 1 | 2018 | 7749 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 447 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 2446 | 0.010 |
Why?
|
| Adult | 1 | 2009 | 16662 | 0.010 |
Why?
|